COMMUNIQUÉS West-GlobeNewswire

uniQure Announces Pricing of Upsized $300 Million Public Offering
26/09/2025
LEXINGTON, Mass. and AMSTERDAM, Sept. 25, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced [...]
OSE Immunotherapeutics, Inserm Transfert et Nantes Université annoncent un partenariat stratégique pour accélérer l’innovation en immunothérapie
26/09/2025
OSE Immunotherapeutics, Inserm Transfert et Nantes Université annoncent un partenariat stratégique pour accélérer l’innovation en immunothérapie Nantes, le 26 septembre 2025, 7 heures – OSE Immunotherapeutics SA ( ISIN [...]
OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy
26/09/2025
OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy NANTES, France – September 26, 2025, 7:00 a.m. – OSE Immunotherapeutics SA (ISIN: [...]
Addex Therapeutics to Report 2025 Half-year and Second Quarter Financial Results on September 30, 2025 and Host Conference Call on October 1, 2025
26/09/2025
Geneva, Switzerland, September 26, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for [...]
Grant of Restricted Stock Units and Warrants to Employees in Genmab
26/09/2025
Company Announcement COPENHAGEN, Denmark; September 26, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 14,353 restricted stock units and 9,681 warrants to employees of the [...]
Harrow Launches Harrow Access for All (HAFA)
25/09/2025
HAFA to Expand Harrow’s Innovative Market Access Model Across Ophthalmic Portfolio Program will be available in late 2025 through the HarrowAccess.com Portal NASHVILLE, Tenn., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Harrow ( [...]
CapsoVision to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
25/09/2025
SARATOGA, Calif., Sept. 25, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced [...]
LifeMD to Participate in the ROTH 4th Annual Healthcare Opportunities Conference
25/09/2025
NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced its participation in the ROTH 4 th Annual Healthcare Opportunities [...]
Medtimo Files Patent Infringement Complaint Against Allurion Technologies
25/09/2025
Complaint Seeks to Protect Medtimo’s Balloon System Technology and Alleges That Allurion Infringes Three Medtimo Patents IRVINE, Calif., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Medtimo Inc , a wholly owned subsidiary of [...]
Buying Guide 2025- most effective female libido booster pills in 2025 By OhYes
25/09/2025
When it comes to the best pill for enhancing a woman's sex life, the answer is simple: Oh Yes. This American-made supplement is packed with some of the most effective, all-natural libido-boosting ingredients available, [...]
Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025
25/09/2025
TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2025 financial results on Wednesday [...]
Teva Releases Q3 2025 Aide Memoire
25/09/2025
TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q3 2025 Aide Memoire is available on the “Investors” page on its website. Q3 2025 [...]
Organogenesis Provides Update on Second Phase 3 ReNu® Study
25/09/2025
Company maintains confidence in ReNu as innovative pain management therapy Second Phase 3 trial demonstrates numerical improvement in baseline pain reduction over the first Phase 3 trial despite not meeting the primary [...]
Medicenna Announces Results of Annual Meeting of Shareholders
25/09/2025
TORONTO and HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of [...]
Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology
25/09/2025
– KOMET-001 in R/R NPM1 -m AML met its primary endpoint with ziftomenib monotherapy demonstrating significant clinical benefit and deep responses – – Consistent activity across pre-specified subgroups, regardless of [...]
Medirom Decides to Double Installation of Authentication Device “Orb” to 200 Stores, in Collaboration with “World” Co-founded by Sam Altman and Alex Blania
25/09/2025
TOKYO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Headquarters: Minato-ku, Tokyo; CEO: Kouji Eguchi; NASDAQ: MRM), a diversified healthcare company, has joined “World,” a “proof of human” [...]
EssilorLuxottica: Essilor Stellest est le tout premier verre optique à recevoir de la FDA une autorisation de mise sur le marché aux États-Unis
25/09/2025
Essilor Stellest est le tout premier verre optique à recevoir de la FDA une autorisation de mise sur le marché aux États-Unis L’efficacité du verre d'EssilorLuxottica pour ralentir la progression de la myopie infantile [...]
EssilorLuxottica: Essilor Stellest is the first and only FDA market authorized spectacle lens in the United States
25/09/2025
Essilor Stellest is the first and only FDA market authorized spectacle lens in the United States EssilorLuxottica’s lens is clinically proven to slow myopia progression in children 1 ,2 Paris, France (25 September 2025 [...]
Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly
25/09/2025
Novel nonpeptide SST2 agonist PALSONIFY advances the treatment paradigm as the first once-daily, oral therapy approved by the FDA to treat acromegaly Approval based on data from two pivotal Phase 3 trials where [...]

Pages